Synthetic cannabinoids and ST elevation myocardial infarction.
Am J Med Sci
; 364(4): 481-491, 2022 Oct.
Article
in English
| MEDLINE | ID: covidwho-2231347
ABSTRACT
Synthetic cannabinoids cannot be detected on a standard urine drug screen (UDS), making them a convenient drug of abuse. We report the first case of ST elevation myocardial infarction (STEMI) in a young patient due to coronary artery thrombosis secondary to synthetic cannabinoid use and concurrent COVID-19 infection. A 38-year-old previously healthy male developed severe chest pain and was found to have anterior STEMI and COVID-19 infection. Coronary angiography showed acute thrombotic occlusion of the mid-left anterior descending artery that was managed with thrombectomy and stent placement. He only required supportive care for COVID-19. A comprehensive literature search revealed 34 additional cases of STEMI with synthetic cannabinoid use; majority were males (97%) with mean age of 29 years. 29 patients (85.3%) underwent coronary angiography and majority had left anterior descending artery (LAD) involvement (55%), with 13 (44.8%) undergoing stent placement. We highlight STEMI as a potentially lethal complication of synthetic cannabinoids; prompt angiography may be lifesaving.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Coronary Thrombosis
/
Cannabinoids
/
ST Elevation Myocardial Infarction
/
COVID-19
Type of study:
Case report
Topics:
Long Covid
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Am J Med Sci
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS